TITLE

New direct thrombin inhibitor becomes available

AUTHOR(S)
Thompson, Cheryl A.
PUB. DATE
April 2010
SOURCE
American Journal of Health-System Pharmacy;4/15/2010, Vol. 67 Issue 8, p588
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article provides information on direct thrombin inhibitor drug Desirudin. It reports that the U.S. Food and Drug Administration (FDA) had approved Desirudin for use in the U.S. in 2003. Canyon Pharmaceuticals Inc. has announced that the drug is now available in the U.S. market. The molecular structure of Desirudin is similar to the anticoagulant secreted by leech. It is a selective inhibitor of clot-bound and free thrombin.
ACCESSION #
48959327

 

Related Articles

  • IN BRIEF: Pharmaceuticals.  // Chemical Market Reporter;8/14/2006, Vol. 270 Issue 5, p22 

    The article offers news briefs related to the pharmaceutical industry in the U.S. The Food and Drug Administration has approved Abbott Laboratories' Humira for the treatment of ankylosing spondylitis. A marketing approval for ATryn, a recombinant form of human antithrombin has been granted GTC...

  • ATryn.  // Formulary;Mar2009, Vol. 44 Issue 3, p70 

    The article reports on the approval of the U.S. Food and Drug Administration (FDA) on recombinant human antithrombin on February 6, 2009. The agent is used for the prevention of perioperative and peripartum thromboembolic events in patients with deficiency in hereditary antithrombin. The...

  • New drugs approved in 2009. Sears, Erin; Brooks, Sarah // Baylor University Medical Center Proceedings;Apr2010, Vol. 23 Issue 2, p175 

    The article reviews medications that were approved by the U.S. Food and Drug Administration (FDA) during 2009. Recombinant antithrombin is used for the prevention of perioperative and peripartum thromboembolic events and dosage is based on patient weight and antithrombin activity level....

  • Dabigatran for stroke in patients with nonvalvular atrial fibrillation. Elliott, William T. // Infectious Disease Alert;Apr2011 Pharmacology Watch, p1 

    The article focuses on direct thrombin inhibitor Dabigatran that has been approved for preventing stroke in patients who have nonvalvular atrial fibrillation. It mentions that rivaroxaban, a direct factor Xa inhibitor is still in the process of gaining the U.S. Food and Drug Administration's...

  • ATryn Wins 1 OK, Loses on Broader Indication.  // Bioworld Week;2/16/2009, Vol. 17 Issue 7, p3 

    The article reports on the approval of the U.S. Food and Drug Administration of the ATryn developed by GTC Biotherapeutics Inc. as a therapy to prevent perioperative and peripartum thromboemblic events in patients with hereditary antithrombin deficiency. However, ATryn failed to gain approval as...

  • Omrix's Shares Climb After Evithrom Wins FDA Approval. Young, Donna // BioWorld Today;8/29/2007, Vol. 18 Issue 168, p1 

    The article reports that the U.S. Food and Drug Administration (FDA) has approved Omrix Biopharmaceutical Inc.'s Evithrom, a standalone human thrombin product. Evithrom is a topical product indicated for use in general surgery procedures to control minor bleeding from capillaries and small...

  • First plasma-free thrombin product approved by FDA. Thompson, Cheryl A. // American Journal of Health-System Pharmacy;3/1/2008, Vol. 65 Issue 5, p380 

    The article reports on the approval granted by the U.S. Food and Drug Administration (FDA) to ZymoGenetics Inc.'s Recothrom, the first recombinant, plasma-free thrombin product. The drug is intended to help stop bleeding from capillaries and small veins after surgery. Incision-site complications...

  • Dabigatran for stroke in patients with nonvalvular atrial fibrillation. Elliott, William T. // Neurology Alert;Apr2011 Clinical Bri, p1 

    The article reports on the U.S. Food and Drug Administration (FDA) approval gained by dabigatran, a direct thrombin inhibitor, for prevention of stroke in patients with nonvalvular atrial fibrillation. Also, the American College of Cardiology, the American Heart Association and the Heart Rhythm...

  • FDA approves first biological product derived from transgenic animal. Lavine, Greg // American Journal of Health-System Pharmacy;3/15/2009, Vol. 66 Issue 6, p518 

    The article reports that on February 6, 2009, the U.S. Food and Drug Administration (FDA) has announced its approval of antithrombin recombinant deficiency, the first biological product made from a genetically engineered animal. FDA relates that the product will be marketed as ATryn which aims...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics